Exo key facts
as of Oct 2026- Developer of a handheld ultrasound device designed for medical imaging and therapeutic applications.
- Exo is valued at approximately $645.0M as of Oct 2026 (last reported valuation).
- It has raised $409.4M; the latest was Debt - General ($7.5M) in Dec 2025.
- Notable investors include RA Capital Management, Samsung Venture Investment, Intel Capital, Sony Innovation Fund, Page One Ventures — 37 tracked in total.
- Status: Privately Held (backing).
Exo's last reported valuation, Apr 2021. Nothing priced has surfaced since.
- ·The complete investor list: 37 names
- ·Watch Exo: the Monday email on marks, rounds and moves
Exo funding rounds
No funding rounds for Exo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Exo
37+Exo valuation
Exo's last reported valuation was $645 million in Apr 2021. No priced round, secondary trade or fund mark has surfaced since.
Exo investors
37 investors are on record for Exo, including RA Capital Management, Samsung Venture Investment, Intel Capital and Sony Innovation Fund. By type, the record holds 11 venture capital firms and 3 family offices.
About Exo
Developer of a handheld ultrasound device designed for medical imaging and therapeutic applications. The company's technology combines advanced nano-materials, novel sensor technologies, advanced signal processing, and computation with the economies of scale of semiconductor manufacturing, enabling healthcare professionals to make critical, real-time decisions that improve patient outcomes at a lower and more convenient cost.
- Sector
- Healthcare
- HQ
- Santa Clara, CA, United States
- Founded
- 2015
- Employees
- 187
- Website
- exo.inc/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.